Amarin Corp. PLC Files Definitive Proxy Statement (DEF 14A)

TL;DR

<b>Amarin Corp. PLC has filed its Definitive Proxy Statement (DEF 14A) for the period ending April 18, 2024.</b>

AI Summary

AMARIN CORP PLC\UK (AMRN) filed a Proxy Statement (DEF 14A) with the SEC on March 4, 2024. Amarin Corp. PLC filed a DEF 14A form on March 4, 2024. The filing pertains to the period ending April 18, 2024. The company's principal executive offices are located in Dublin, Ireland. Amarin Corp. PLC was formerly known as Amarin Pharmaceuticals PLC and Ethical Holdings PLC. The filing includes details on executive compensation and equity awards.

Why It Matters

For investors and stakeholders tracking AMARIN CORP PLC\UK, this filing contains several important signals. This filing is crucial for shareholders as it outlines executive compensation, voting matters, and other corporate governance information ahead of the annual meeting. Understanding the details within the DEF 14A can help investors make informed decisions regarding their votes on proposals and their assessment of the company's leadership and financial health.

Risk Assessment

Risk Level: low — AMARIN CORP PLC\UK shows low risk based on this filing. The filing is a routine proxy statement and does not contain new financial results or significant operational updates, indicating a low level of immediate risk.

Analyst Insight

Shareholders should review the executive compensation and voting proposals detailed in this DEF 14A to make informed decisions at the upcoming meeting.

Key Numbers

• 2024-04-18 — Conformed Period of Report (CONFORMED PERIOD OF REPORT)
• 2024-03-04 — Filed As Of Date (FILED AS OF DATE)
• 2023-12-31 — Fiscal Year End (FISCAL YEAR END)
• 2000-02-01 — Date of Name Change (FORMER COMPANY DATE OF NAME CHANGE)

Key Players & Entities

• AMARIN CORP PLC\UK (company) — FILER
• 0000897448 (company) — CENTRAL INDEX KEY
• 2834 (company) — STANDARD INDUSTRIAL CLASSIFICATION
• SPACES SOUTH DOCKLANDS, BLOCK C (company) — BUSINESS ADDRESS STREET 1
• 77 SIR JOHN ROGERSON'S QUAY (company) — BUSINESS ADDRESS STREET 2
• DUBLIN 2 (company) — BUSINESS ADDRESS CITY
• 353 1 6699 020 (company) — BUSINESS PHONE
• AMARIN PHARMACEUTICALS PLC (company) — FORMER COMPANY

FAQ

Industry Context

Amarin Corp. PLC operates in the pharmaceutical preparations industry. This filing is a standard proxy statement for a publicly traded company.

Regulatory Implications

This filing is made under the Securities Exchange Act of 1934, specifically Form DEF 14A, which requires companies to provide detailed information to shareholders before their annual meeting.

What Investors Should Do

1. Review executive compensation details for key personnel.
2. Understand the proposals to be voted on at the shareholder meeting.
3. Note the company's historical name changes and incorporation details.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for annual shareholder meetings and does not represent a change from previous filings of this type.

Key Financial Figures

• $50 million — anuary a share repurchase plan of up to $50 million. The Board knows there is more work t
• $25,500 — nd solicitation of proxies for a fee of $25,500 plus expenses. Our directors, officers

Filing Documents

• amrn-20240304.htm (DEF 14A) — 2594KB
• img153232652_0.jpg (GRAPHIC) — 8KB
• img153232652_1.jpg (GRAPHIC) — 38KB
• img153232652_2.jpg (GRAPHIC) — 33KB
• img153232652_3.jpg (GRAPHIC) — 33KB
• 0000950170-24-024353.txt (&nbsp;) — 4081KB
• amrn-20240304.xsd (EX-101.SCH) — 39KB
• amrn-20240304_htm.xml (XML) — 375KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 31

EXECUTIVE COMPENSATION DISCUSSION AND ANALYSIS

EXECUTIVE COMPENSATION DISCUSSION AND ANALYSIS 33 2023 Operating Highlights 33 Compensation Philosophy and Objectives 34 Chief Executive Officer Performance and Compensation 35 REMUNERATION COMMITTEE REPORT 46 2023 Summary Compensation Table 47 Option Exercises and Stock Vested 51 Outstanding Equity Awards at Fiscal Year-End 2023 52 Pension Benefits 54 Nonqualified Deferred Compensation 54 i Change of Control and Severance Arrangements 54 Potential Payments upon Termination or Change in Control 56 Chief Executive Officer Pay Ratio 57 DIRECTOR COMPENSATION 62 Non-Employee Director Compensation 62 Director Compensation Table 64 Director Stock Ownership Guidelines 65 REPORT OF THE AUDIT COMMITTEE 65 PROPOSALS 67 DELIVERY OF PROXY MATERIALS 68 Appendix A Amendment NO. 3 to 2020 Stock Incentive Plan 69 Appendix B Articles of Association 70 ii PROXY STATEMENT FOR 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON APRIL 18, 2024 GENERAL INFORMATION This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of Directors (the " Board ") of Amarin Corporation plc, a public limited company registered in England & Wales (" Amarin ", the " Company ", " we " or " us ") for use at the Company's 2024 Annual General Meeting of Shareholders (the " Annual General Meeting ") to be held at the Dublin offices of Arthur Cox LLP, Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland on April 18, 2024 at 9:00 a.m. local time, or at any adjournment thereof, for the purpose of considering and, if thought fit, passing the resolutions specified in the Notice of Annual General Meeting. This Proxy Statement is being sent to shareholders on or about March 4, 2024. Please vote on the resolutions specified in the Notice of Annual General Meeting by appointing a proxy. A form of proxy for use by holders of Ordinary Shares at the Annual General Meeting is enclose

View Full Filing

View this DEF 14A filing on SEC EDGAR